A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
New England Journal of Medicine·
- DOI
- 10.1056/nejmoa1411627
- PMID
- 25629663
- PMCID
- PMC5798586
- OpenAlex
- W2343314930
- Study type
- Journal article
- Publisher
- Massachusetts Medical Society
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Development of an effective Ebola vaccine was identified as a priority for controlling future outbreaks following the West African epidemic that caused over 11,000 deaths.
Structured evidence summary
Research question
This phase 1 trial examined the safety and immunogenicity of a chimpanzee adenovirus 3 vaccine encoding the Zaire ebolavirus surface glycoprotein, administered alone or with a modified vaccinia Ankara booster.
Study design
Phase 1 dose-escalation trial with 60 healthy adults receiving one of three dose levels of ChAd3-ZEBOV vaccine. Thirty participants received an MVA booster, and 16 additional participants evaluated a shortened prime-boost interval. Antibody and T-cell responses were compared to those from rVSV-ZEBOV vaccine trials.
Population and setting
Sixty healthy adult volunteers enrolled in Oxford, United Kingdom.
Main findings
No safety concerns emerged at any dose level. Four weeks post-vaccination, ChAd3-ZEBOV induced ZEBOV-specific antibody responses and neutralization activity comparable to rVSV-ZEBOV. Addition of the MVA booster increased virus-specific antibodies 12-fold and glycoprotein-specific CD8+ T cells 5-fold, with neutralizing antibodies rising significantly in all 30 boosted participants.
Public-health relevance
Development of an effective Ebola vaccine was identified as a priority for controlling future outbreaks following the West African epidemic that caused over 11,000 deaths.
Important limitations
This summary relies on the supplied single-article abstract and metadata. Full interpretation of vaccine efficacy, durability, population generalizability, and safety profile requires the complete published study.
GIDS interpretation
The study is linked to Ebola and hemorrhagic fever disease classifiers, the Democratic Republic of the Congo and United Kingdom, and topics including outbreak investigation, treatment, and vaccination. These links reflect article content and facilitate discoverability within broader surveillance literature; they do not indicate real-time signal activity or current outbreak status.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.